Milestone Pharma Seeks FDA Approval For Treatment Of Abnormal Heart Rhythm

(RTTNews) - Milestone Pharmaceuticals Inc. (MIST) announced the submission of a New Drug Application to the U.S. Food and Drug Administration for etripamil for the treatment of paroxysmal supraventricular tachycardia or PSVT. The submission seeks approval for treatment of an abnormal heart rhythm.

PVST is a condition characterized by an abnormality in the electrical system of the heart causing patients to have unexpected, often severely symptomatic episodes of rapid heart rate.

The Comprehensive data package includes positive results from pivotal Phase 3 RAPID trial which Company believes demonstrates new calcium channel blocker, etripamil, is twice as effective and three times as fast as a placebo in restoring normal heart rhythm for patients suffering from PSVT.

CARDAMYST, the conditionally approved brand name for etripamil nasal spray, if approved, will be the first rapid, reliable and at-the-ready option in the treatment of serious heart arrhythmias, the company said.

For More Such Health News, visit rttnews.com